Published in Alzheimer Dis Assoc Disord on January 01, 1998
TNF-alpha and neuropathic pain--a review. J Neuroinflammation (2010) 1.68
Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR Biomed (2006) 0.99
Chronic administration of the methylxanthine propentofylline impairs reinstatement to cocaine by a GLT-1-dependent mechanism. Neuropsychopharmacology (2013) 0.91
Vascular dementia: prevention and treatment. Clin Interv Aging (2006) 0.87
Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr Neuropharmacol (2008) 0.83
Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway. J Neurooncol (2015) 0.75
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology (1998) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord (1999) 2.30
Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology (2011) 2.19
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12
White matter hyperintensities on MRI in the neurologically nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke (1995) 2.01
White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol (1993) 1.86
CT and MRI rating of white matter lesions. Cerebrovasc Dis (2002) 1.83
A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging (2000) 1.78
Short Portable Mental Status Questionnaire as a screening test for dementia and delirium among the elderly. J Am Geriatr Soc (1987) 1.76
Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci (2011) 1.66
Social functioning in depression: a review. J Clin Psychiatry (2000) 1.62
Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology (2000) 1.60
Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol (2001) 1.59
Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke (1997) 1.56
Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry (2000) 1.53
Moderate alcohol consumption and loss of cerebellar Purkinje cells. BMJ (1994) 1.53
White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology (2004) 1.47
The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology (2007) 1.46
White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology (2010) 1.44
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J Psychopharmacol (2000) 1.39
[Constipation after tilidine/naloxone and tramadol in comparison to codeine. A dose response study in human volunteers]. Schmerz (1996) 1.38
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother (2011) 1.36
Clinical determinants of poststroke dementia. Stroke (1998) 1.36
Do white matter changes on MRI and CT differentiate vascular dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry (1987) 1.36
Variable agreement between visual rating scales for white matter hyperintensities on MRI. Comparison of 13 rating scales in a poststroke cohort. Stroke (1997) 1.33
White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry (2007) 1.31
Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett (2000) 1.31
White matter changes in stroke patients. Relationship with stroke subtype and outcome. Eur Neurol (1999) 1.29
Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. J Neurol Neurosurg Psychiatry (2009) 1.28
Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology (1997) 1.27
Executive functions and speed of mental processing in elderly patients with frontal or nonfrontal ischemic stroke. Eur J Neurol (1999) 1.27
Vascular dementia due to cardiac arrhythmias and systemic hypotension. Acta Neurol Scand (1987) 1.27
Dementia among medical inpatients. Evaluation of 2000 consecutive admissions. Arch Intern Med (1986) 1.27
Comparative efficacy of antidepressants. Drugs (1992) 1.25
Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabet Med (2007) 1.25
White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. J Neurol Neurosurg Psychiatry (2005) 1.24
Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology (2010) 1.22
Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man. J Biol Chem (1980) 1.21
Poststroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci (2004) 1.21
Frequency and clinical determinants of poststroke depression. Stroke (1998) 1.20
EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol (2012) 1.19
Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. Cerebrovasc Dis (2008) 1.17
Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology (2012) 1.17
Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry (2006) 1.16
Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging (2006) 1.15
Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res (1999) 1.13
[Psychometric evaluation of the German version of the Barratt Impulsiveness Scale]. Nervenarzt (2008) 1.12
Pulp capping of carious exposures: treatment outcome after 5 and 10 years: a retrospective study. J Endod (2000) 1.10
Post-stroke depression, executive dysfunction and functional outcome. Eur J Neurol (2002) 1.10
Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. J Neurol (2006) 1.10
Megaloblastic maturation masked by iron deficiency: a biochemical basis. Br J Haematol (1972) 1.09
How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol (2000) 1.09
Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord (2000) 1.08
The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci (1998) 1.08
Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol (1999) 1.07
[Help-seeking behavior and compliance of suicidal patients]. Psychiatr Prax (1984) 1.06
Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet (1995) 1.06
Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research concensus statement. Can J Neurol Sci (1994) 1.06
[Transcranial magnetic stimulation. A diagnostic means from neurology as therapy in psychiatry?]. Nervenarzt (1997) 1.06
Insomnia in ischemic stroke patients. Cerebrovasc Dis (2002) 1.06
Clinical significance of corpus callosum atrophy in a mixed elderly population. Neurobiol Aging (2006) 1.04
Functional assessment scales in detecting dementia. Age Ageing (1997) 1.04
Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics (1997) 1.02
Correction for age, education and other demographic variables in the use of the Mini Mental State Examination in Finland. Acta Neurol Scand (1992) 1.02
Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med (2009) 1.01
Magnetic resonance imaging white matter hyperintensities and mechanism of ischemic stroke. Stroke (1999) 1.01
What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review? Bipolar Disord (2008) 1.00
CSF beta-endorphin and beta-lipotropin in Alzheimer's disease and multi-infarct dementia. Neurology (1985) 0.99
Magnetic resonance imaging correlates of depression after ischemic stroke. Arch Gen Psychiatry (2001) 0.99
Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci (2004) 0.98
Occupations with exposure to electromagnetic fields: a possible risk factor for Alzheimer's disease. Am J Epidemiol (1995) 0.98
White matter changes contribute to corpus callosum atrophy in the elderly: the LADIS study. AJNR Am J Neuroradiol (2008) 0.97
Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol (1985) 0.97
MRI correlates of executive dysfunction in patients with ischaemic stroke. Eur J Neurol (2003) 0.97
Major depression in the elderly: a population study in Helsinki. Int Psychogeriatr (1996) 0.97
Postural hypotension and dizziness in a general aged population: a four-year follow-up of the Helsinki Aging Study. J Am Geriatr Soc (1996) 0.96
Association between salivary flow rate and the use of systemic medication among 76-, 81-, and 86-year-old inhabitants in Helsinki, Finland. J Dent Res (1992) 0.96
Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. J Neurol Neurosurg Psychiatry (2005) 0.96
Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state. Eur J Clin Pharmacol (1983) 0.96
Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Stroke (1997) 0.96
Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life". Eur Arch Psychiatry Clin Neurosci (2000) 0.96
Extended survival of patients on long-term lithium treatment. Can J Psychiatry (1995) 0.95
Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr (1970) (1980) 0.95
The psychiatric management of parasuicide patients: a controlled clinical study comparing different strategies of outpatient treatment. Crisis (1987) 0.94
Snoring, sleep apnea syndrome, and stroke. Neurology (1992) 0.94
Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. J Cardiovasc Pharmacol (1986) 0.94
Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics (1998) 0.93
Neuropsychological differentiation between normal aging, Alzheimer's disease and vascular dementia. Acta Neurol Scand (1986) 0.93
The neural basis of the P300 potential. Focus on the time-course of the underlying cortical generators. Eur Arch Psychiatry Clin Neurosci (2004) 0.93
Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1 alpha in man. Biochim Biophys Acta (1980) 0.93
MRI of the brain in neurologically healthy middle-aged and elderly individuals. Neuroradiology (1997) 0.92
Cognitive impairment predicts poststroke death in long-term follow-up. J Neurol Neurosurg Psychiatry (2009) 0.92
The effect of the skull on event-related P300. Clin Neurophysiol (2001) 0.92
Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? Br J Clin Pharmacol (1986) 0.92